Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson's disease population : an open-label, levodopa add-on study
Abstract: Background Safinamide is a recent multimodal antiparkinsonian drug that inhibits monoamine oxidase B and modulates the glutamatergic system with positive effects on motor and nonmotor symptoms of Parkinson's disease (PD). This post-hoc analysis of the European SYNAPSES study provides first-time data on the use of safinamide in routine clinical practice in Belgium. Objective To describe the efficacy and safety of safinamide in Belgian PD patients in real-life conditions. Methods Post-hoc analysis of the Belgian cohort from the European SYNAPSES trial, which was an observational, multi... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2023 |
Schlagwörter: | Human medicine |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26527642 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://hdl.handle.net/10067/1914270151162165141 |